Please assess the completion status of the following clinical trial:

Trial Title: A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 18 and 50 years of age, inclusive~* Females of non-childbearing potential (as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea~* Body weight \> 50 kg and BMI within the range 19 - 31 kg/m2 (inclusive)~* QTcB or QTcF \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block~Exclusion Criteria:~* Positive pre-study drug/alcohol screen~* Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.~* A positive test for HIV antibody~* History of regular alcohol consumption within 6 months of the study~* Participation in a clinical trial with an investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer) prior to start of the new study~* Exposure to more than four new drugs or within 12 months prior to the first dosing day~* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication~* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that would be contraindicated~* Donation of blood or blood products in excess of 500 mL within a 56 day period.~* Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.~* Lactating females.~* Unwillingness or inability to follow the procedures outlined in the protocol.~* History of sensitivity to heparin or history of heparin-induced thrombocytopenia if heparin is used to maintain the patency of an intravenous cannula.~* Asthma or a history of asthma~* Smoking or history or regular use of tobacco- or nicotine-containing products within 2 months prior to screening~* Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Single Dose, Repeat Dose, Drug-Drug Interaction (Type: EXPERIMENTAL): GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.~To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues